Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation to Present at Upcoming Investor Conferences

11/12/2021 | 07:31am EST

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.

  • Stifel’s 2021 Virtual Healthcare Conference being held November 15-17. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST.
  • Stephens Annual Investment Conference being held December 1-3. Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Friday, December 3, at 11:00 a.m. EST.

A live webcast of the discussions will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

 


All news about REPLIGEN CORPORATION
01/12Repligen Seeks Acquisitions
CI
01/04REPLIGEN CORP : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
01/04Repligen Corporation Promotes James Bylund to the Chief Operating Officer and Principal..
CI
2021Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021REPLIGEN CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
2021Repligen Corporation acquired Bio-Flex Solutions, L.L.C. / Newton T & M Corp.
CI
2021INSIDER SELL : Repligen
MT
2021INSIDER SELL : Repligen
MT
2021Repligen Corporation to Present at Upcoming Investor Conferences
GL
2021Repligen Releases Inaugural Sustainability Report
AQ
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 662 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 79,0x
Yield 2021 -
Capitalization 9 790 M 9 790 M -
EV / Sales 2021 14,1x
EV / Sales 2022 11,5x
Nbr of Employees -
Free-Float -
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 177,07 $
Average target price 312,56 $
Spread / Average Target 76,5%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION-31.45%9 790
ABBOTT LABORATORIES-14.42%206 551
MEDTRONIC PLC-0.26%138 731
BECTON, DICKINSON AND COMPANY0.96%71 600
HOYA CORPORATION-18.59%44 518
BAXTER INTERNATIONAL INC.-1.41%42 374